Drug updated on 11/14/2023

Dosage FormTablet (oral: 200 mg)
Drug ClassAntimycobacterials
Ongoing and Completed


  • Indicated, as part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary extensively drug resistant (XDR), treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB).

Product Monograph / Prescribing Information

Document TitleYearSource
Pretomanid Prescribing Information.2019The Global Alliance for TB Drug Development, New York, NY

Systematic Reviews / Meta-Analyses

Document TitleYearSource
Pretomanid for tuberculosis: a systematic review.2022Clinical Microbiology and Infection

Clinical Practice Guidelines